Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Research & Development: 2023-2024

Historic Research & Development for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $38.4 million.

  • Contineum Therapeutics' Research & Development rose 62.44% to $13.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $38.4 million, marking a year-over-year increase of 39.20%. This contributed to the annual value of $38.4 million for FY2024, which is 39.20% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Research & Development of $38.4 million as of FY2024, which was up 39.20% from $27.6 million recorded in FY2023.
  • Over the past 5 years, Contineum Therapeutics' Research & Development peaked at $38.4 million during FY2024, and registered a low of $27.6 million during FY2023.
  • For the 2-year period, Contineum Therapeutics' Research & Development averaged around $33.0 million, with its median value being $33.0 million (2023).
  • Data for Contineum Therapeutics' Research & Development shows a peak YoY spiked of 39.20% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Research & Development (Yearly) stood at $27.6 million in 2023, then soared by 39.20% to $38.4 million in 2024.